Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Phase III Data Validate Clinical Trial Design In Lupus

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Over a span of little more than a month this summer, the face of clinical trials for lupus drugs changed considerably for the better.

You may also be interested in...



How A Biomarker Revived Synta’s Cancer Drug Elesclomol

Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.

How A Biomarker Revived Synta’s Cancer Drug Elesclomol

Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.

Late-Stage Lupus Therapies Glow In Halo Of Benlysta Spotlight

If Human Genome Sciences/GlaxoSmithKline’s Benlysta (belimumab) succeeds in becoming the first new lupus therapy in half a century to make it through the regulatory gauntlet, it could change not only the commercial outlook in the lupus market, but also the landscape of future lupus clinical trial design.

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel